TICKERNERD
Menu
CDNACDNAHealthcare · Diagnostics & Research

CDNA Stock Forecast: CareDx, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$65
−1.13% on the day

The 7 Wall Street analysts covering CareDx, Inc. hold a median 12-month price target of $65 — -0.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 14 Oct 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$3.4B
Ticker Nerd rank
99 / 100
Median analyst target
$65
Analysts covering
7
Revenue$131.9M+52.2% y/y
Operating income$257K
Net income$110.6M
Free cash flow$28.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.6%
1M
+23.5%
YTD
+243.4%
1Y
+350.8%
From 52W high
−7.4%
From 52W low
+353.0%
$14
$70
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CDNA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CareDx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
100
Quality
99
Revisions
97
Issuance
95
Value
79
Growth
73
Accruals
51
Volatility
41
Size
28

Momentum (100): The shares have been drifting up relative to others.

Volatility (41): The share price moves around a lot.

Size (28): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CDNA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CDNA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70$80Jan 26Apr 26Jul 26Oct 26CDNAHigh $75Median $65Low $46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
5 Buy2 Hold0 Sell
Low $46Median $65High $75

The green dot is the last close — the median target sits −0.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
24 Sept 2026BTIGMaintainsBuy$60 → $74
2 Sept 2026Canaccord GenuityInitiatesBuy$65
2 Sept 2026Canaccord GenuityInitiatesBuy—
6 Aug 2026BTIGMaintainsBuy$45 → $60
6 Aug 2026BTIGMaintainsBuy—
31 July 2026HC Wainwright & Co.ReiteratesNeutral$46
31 July 2026HC Wainwright & Co.ReiteratesNeutral—
16 July 2026BTIGMaintainsBuy$28 → $45
16 July 2026BTIGMaintainsBuy—
29 Apr 2026BTIGMaintainsBuy$26 → $28
29 Apr 2026BTIGMaintainsBuy—
26 Feb 2026BTIGMaintainsBuy—
25 Feb 2026Wells FargoMaintainsEqual-Weight—
15 Dec 2025Wells FargoMaintainsEqual-Weight—
6 Nov 2025BTIGMaintainsBuy—
23 Sept 2025BTIGReiteratesBuy—
12 Sept 2025BTIGReiteratesBuy—
26 Aug 2025William BlairInitiatesMarket Perform—
8 Aug 2025Wells FargoMaintainsEqual-Weight—
18 July 2025Craig-HallumMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CDNA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CDNA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, CareDx, Inc. returned +350.8% against +17.5% for the S&P 500, dividends included.

CDNA vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26CDNAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CDNA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+28.3%
Analysts raising
5
Analysts cutting
0
Fundamentals

CareDx, Inc. (CDNA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
31.2×

Cheaper than 24% of US stocks

Price / sales
7.4×

Cheaper than 17% of US stocks

Price / book
7.9×

Cheaper than 12% of US stocks

EV / EBITDA
234.1×

Cheaper than 1% of US stocks

Growth & margins
Revenue growth (YoY)
52.2%

Higher than 86% of US stocks

Earnings growth (YoY)
52.2%

Higher than 75% of US stocks

Gross margin
73.5%

Higher than 86% of US stocks

Operating margin
0.2%

Higher than 46% of US stocks

Net margin
24.2%

Higher than 85% of US stocks

Returns & dividend
Return on equity
29.5%

Higher than 87% of US stocks

Return on assets
−0.3%

Higher than 42% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

CareDx, Inc. (CDNA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • CareDx, Inc. has a market value of $3.4B and an enterprise value of $2.9B.

  • Revenue in the twelve months to 30 June 2026: $458.1M. The latest quarter grew 52.2% year on year.

  • Net income over the same four quarters: $111.0M, a 24.2% net margin.

  • Diluted earnings per share, trailing twelve months: $2.07.

  • Free cash flow in the twelve months to 30 June 2026: $84.0M.

  • Shares outstanding: 51.5M.

  • Trailing P/E: 31.2×; forward P/E: 50.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • CareDx, Inc. employs 761 people — $602K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

CDNA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
CDNACareDx, Inc.$3.4B
99
VCYTVeracyte, Inc.$3.5B
96
ADPTAdaptive Biotechnologies Corp.$4.1B
73
BLLNBillionToOne, Inc.$4.6B
15
SHCSotera Health Co.$5.0B
97
NEONeoGenomics, Inc.$2.2B
81
RDNTRadNet, Inc.$5.4B
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CareDx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CDNA news & analysis

CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?

Zacks Investment Research · 25 Sept 2026neutral

CareDx's share price jumped 13.0% in the last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock does not suggest further strength down the road, according to the report.

Why it matters — A CDNA watcher would care because the stock's recent jump contrasts with a weaker earnings estimate revision trend, signaling uncertainty about whether momentum can be sustained.

Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently

Benzinga · 23 Sept 2026neutral

The Centers for Medicare & Medicaid Services plans to align its 2027 clinical laboratory fee schedule rates with private sector payer rates, which it says aims to curb excessive Medicare payments and save taxpayers an estimated $1 billion annually. The change is reported to affect BillionToOne and CareDx differently.

Why it matters — CareDx, as a clinical laboratory company receiving Medicare reimbursement, could see its 2027 fee schedule payments affected by this rate-alignment change.

5 Top-Ranked High-Efficiency Stocks With Strong Profit Potential

Zacks Investment Research · 23 Sept 2026neutral

Zacks Investment Research highlighted five top-ranked stocks known for high efficiency, citing strong receivables, asset, inventory, and operating margin metrics. The article does not specifically mention CareDx among the named stocks.

Why it matters — CareDx watchers may note the criteria used for identifying efficient stocks, though the company is not explicitly referenced in the article.

4 Healthcare Stocks to Play Safe as Fed Gears Up for Rate Hike

Zacks Investment Research · 14 Sept 2026neutral

Zacks Investment Research highlights AMGN, BHC, CDNA and CNC as defensive healthcare stock plays amid rising inflation and expectations of a possible Federal Reserve rate hike.

Why it matters — The piece positions CDNA within a group of defensive healthcare names that could be relatively attractive to investors in a rate-hike environment.

Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks

Zacks Investment Research · 9 Sept 2026positive

Zacks Investment Research highlights CareDx (CDNA) as one of four defensive stock picks amid market volatility driven by rising oil prices and escalating Middle East tensions. CDNA is presented alongside COCO, CHEF, and ASMB as a defensive holding.

Why it matters — CareDx is being singled out as a defensive pick during market turbulence, which could draw attention to the stock from investors seeking stability.

FAQ

Frequently asked questions about CDNA stock

What is the CDNA stock price forecast for 2026-2027?

The 7 Wall Street analysts covering CareDx, Inc. have a median 12-month price target of $65, with estimates ranging from $46 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CDNA stock a buy right now?

Of the 7 analysts covering CareDx, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CareDx, Inc. 99 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CDNA?

As at 14 Oct 2026, CareDx, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (100 of 100).

Will CDNA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies -0.3% from the last close, and Ticker Nerd's factor model ranks CareDx, Inc. 99 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CDNA stock forecast for 2030?

No analyst covering CareDx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDNA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $75 over the next 12 months.

How has CDNA stock performed over the past year?

CareDx, Inc. returned +350.8% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CareDx, Inc. do?

CareDx, Inc. is a precision medicine diagnostics company focused on transplant care and related specialty services.

What is the latest news on CDNA?

The most recent item we track (Zacks Investment Research, 25 Sept 2026): "CareDx (CDNA) Stock Jumps 13.0%: Will It Continue to Soar?". CareDx's share price jumped 13.0% in the last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock does not suggest further strength down the road, according to the report.

Company

About CareDx, Inc.

CareDx, Inc. is a precision medicine diagnostics company focused on transplant care and related specialty services. CareDx develops and commercializes non-invasive molecular tests, laboratory products, digital tools, and patient support services that help clinicians monitor organ health before and after transplantation. Its portfolio includes testing solutions for kidney, heart, and lung transplant patients, along with HLA typing and other transplant laboratory products used to support donor-recipient matching and post-transplant surveillance. The company also offers workflow software, data analytics, and care-management tools that connect transplant centers, patients, and providers across the care journey. In addition to its core transplant business, CareDx serves specialty oncology and cell therapy markets with precision diagnostics and support solutions. CareDx, Inc. is headquartered in Brisbane, California.

CEO Mr. John Walter Hanna Jr. · 761 employees · United States · https://caredx.com